Drug Interactions between acitretin and conjugated estrogens / medroxyprogesterone
This report displays the potential drug interactions for the following 2 drugs:
- acitretin
- conjugated estrogens/medroxyprogesterone
Interactions between your drugs
medroxyPROGESTERone acitretin
Applies to: conjugated estrogens / medroxyprogesterone and acitretin
CONTRAINDICATED: Acitretin interferes with the contraceptive effect of microdosed progestin preparations. The mechanism of interaction has not been described, and it is not known whether the effectiveness of implantable or injectable products are affected.
MANAGEMENT: Because use of acitretin is associated with major birth defects, microdosed 'minipill' progestin preparations are not recommended for women of childbearing potential treated with acitretin. It is not known whether other progestational contraceptives such as implants and injectables offer adequate contraception during acitretin therapy. Simultaneous use of at least two methods of effective contraception is mandatory during acitretin therapy and for at least 3 years after discontinuing therapy. Input from a gynecologist or similar expert on adequate contraception should be sought as needed.
References (2)
- Berbis P, Bun H, Geiger JM, Rognin C, Durand a, Serradimigni A, Hartmann D, Privat Y (1988) "Acitretin (RO10-1670) and oral contraceptives: interaction study." Arch Dermatol Res, 280, p. 388-9
- (2001) "Product Information. Soriatane (acitretin)." Roche Laboratories
Drug and food interactions
acitretin food
Applies to: acitretin
CONTRAINDICATED: Ethanol consumption with acitretin leads to the formation of etretinate, which has a much longer half-life than acitretin. Major human fetal abnormalities have been associated with the administration of acitretin, etretinate, and other retinoids. The longer elimination half-life of etretinate relative to acitretin increases the duration of teratogenic potential for female patients. In one case report of a patient with apparent sporadic ethanol intake, etretinate was present in plasma and fat for 52 months after acitretin was discontinued.
MANAGEMENT: Female patients should be warned that ethanol is contraindicated during active treatment with acitretin and for two months after cessation of therapy.
References (4)
- (2001) "Product Information. Soriatane (acitretin)." Roche Laboratories
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
conjugated estrogens food
Applies to: conjugated estrogens / medroxyprogesterone
Coadministration with grapefruit juice may increase the bioavailability of oral estrogens. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits. In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%. Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol. However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability. Also, the effect on other estrogens has not been studied.
References (2)
- Weber A, Jager R, Borner A, et al. (1996) "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception, 53, p. 41-7
- Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T (1995) "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet, 20, p. 219-24
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.